Odonate Therapeutics Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Total Funding:N/A
Industry:Biotech
Founded:2016
Lead Investor(s):N/A

City Ranking

Industry Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Odonate Therapeutics's estimated annual revenue is currently $9.3M per year.
  • Odonate Therapeutics's estimated revenue per employee is $72,656

Employee Data

  • Odonate Therapeutics has 128 Employees.
  • Odonate Therapeutics grew their employee count by 5% last year.
  • Odonate Therapeutics currently has 3 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
DiaCarta
$7M4510%N/A-N/A
Geron Corporati...
N/A205N/AN/A-N/A
Rigel Pharmaceu...
$46.8M3024%N/A-N/A
Althea Technolo...
$22.3M144N/AN/A-N/A
INOVA Diagnosti...
$44.3M286N/AN/A-N/A
10X Genomics
$101.2M65346%N/A-N/A
ProTrials Resea...
$33.3M2153%N/A-N/A
Advanced Cell D...
$28.7M1858%N/A-N/A
The J. Craig Ve...
$39.4M254N/AN/A-N/A
CellMax Life
$6.5M4214%N/A-N/A
Missing a competitor? Contribute!?
Submit

Odonate Therapeutics is dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, an investigational, orally administered taxane. We are conducting our multinational, multicenter, randomized, Phase 3 study in locally advanced or metastatic breast cancer (MBC), known as CONTESSA. Our goal is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.

keywords:N/A

128

Number of Employees

$9.3M

Revenue (est)

3

Current Jobs

5%

Employee Growth %

N/A

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Odonate Therapeutics News

09/07/2019 - Odonate Therapeutics, Inc. (:ODT) Shares Dip Under Moving ...

Shares of Odonate Therapeutics, Inc. (:ODT) have been on a recent steady downtrend, causing some worry for shareholders. Investors may be ...

09/08/2019 - Odonate Therapeutics, Inc. (ODT) Loses -5.39% Worth of ...

Shares of Odonate Therapeutics, Inc. (ODT) have been trending lower over the past five bars, revealing bearish momentum for the shares, ...

09/06/2019 - Carillon Tower Advisers Inc. Purchases Shares of 459968 ...

Carillon Tower Advisers Inc. purchased a new stake in shares of Odonate Therapeutics Inc (NASDAQ:ODT) during the 2nd quarter, according ...